{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:42:35Z","timestamp":1790484155461,"version":"4.1.0"},"reference-count":23,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2018]]},"abstract":"<b><i>Background:<\/i><\/b> Antistaphylococcal penicillins have historically been regarded as the drugs of choice for methicillin-susceptible <i>Staphylococcus aureus<\/i> (MSSA) bloodstream infections (BSI). However, recent outcomes data compared to cefazolin treatment are conflicting. <b><i>Objective:<\/i><\/b> This study compared treatment failure and adverse effects associated with nafcillin and cefazolin for MSSA BSI. <b><i>Methods:<\/i><\/b> Adult inpatients with MSSA BSI between January 1, 2009 and August 31, 2015 were included in this retrospective cohort study if they received \u226572 h of nafcillin or cefazolin as directed therapy after no more than 72 h of any empiric therapy. The primary composite endpoint was treatment failure defined by clinician documentation, 30-day recurrence of infection, all-cause 30-day in-hospital mortality, or loss to follow-up. Secondary outcomes included antibiotic-related acute kidney injury (AKI), acute interstitial nephritis (AIN), hepatotoxicity, and rash. <b><i>Results:<\/i><\/b> Among 157 patients, 116 (73.9%) received nafcillin and 41 (26.1%) received cefazolin. The baseline characteristics were similar except cefazolin-treated patients had higher APACHE II scores and more frequent renal dysfunction. No difference in the composite treatment failure outcome (28.4 vs. 31.7%; <i>p<\/i> = 0.69) was detected between the nafcillin and cefazolin groups, respectively. In a sensitivity analysis excluding patients without known follow-up, there was no significant difference of treatment failure. AKI, AIN, hepatotoxicity, and rash were all numerically more frequent among nafcillin-treated patients. <b><i>Conclusions:<\/i><\/b> Among nafcillin- or cefazolin-treated patients with MSSA BSI, there was no significant difference in treatment failure. Observing more frequent presumptive adverse effects associated with nafcillin receipt, future prospective studies evaluating cefazolin appear warranted.<\/jats:p>","DOI":"10.1159\/000499033","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T21:06:25Z","timestamp":1554843985000},"page":"345-351","source":"Crossref","is-referenced-by-count":12,"title":["Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible <b><i>Staphylococcus aureus<\/i><\/b> Bloodstream Infections"],"prefix":"10.1159","volume":"63","author":[{"given":"Corey\u00a0C.","family":"Burrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor\u00a0K.","family":"Broadbent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham\u00a0M.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard\u00a0S.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica\u00a0V.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth\u00a0B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ308"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-279"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-07"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu301"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0561"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04677-14"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00485-11"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00243-16"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2018.02.004"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2018.07.006"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01816-17"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3418-9"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13554"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky259"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.Supplement_1.S157"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02800-14"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0148-z"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00317-09"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy123"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00382-18"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix287"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1892"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/499033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/499033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:24:13Z","timestamp":1745425453000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000499033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,4,30]]},"published-print":{"date-parts":[[2019,5,2]]}},"URL":"https:\/\/doi.org\/10.1159\/000499033","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}